Background: BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests the existence of genetic and nongenetic modifying factors. In this study, we evaluated the putative role of variants in many candidate modifier genes.
Methods: Genotyping data from 15,252 BRCA1 and 8,211 BRCA2 mutation carriers, for known variants (n = 3,248) located within or around 445 candidate genes, were available through the iCOGS custom-designed array. Breast and ovarian cancer association analysis was performed within a retrospective cohort approach.
Results: The observed P values of association ranged between 0.005 and 1.000. None of the variants was significantly associated with breast or ovarian cancer risk in either BRCA1 or BRCA2 mutation carriers, after multiple testing adjustments.
Conclusion: There is little evidence that any of the evaluated candidate variants act as modifiers of breast and/or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers.
Impact: Genome-wide association studies have been more successful at identifying genetic modifiers of BRCA1/2 penetrance than candidate gene studies.
©2014 American Association for Cancer Research.
Conflict of interest statement
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1362-70. doi: 10.1158/1055-9965.EPI-12-0229. Epub 2012 Jun 22. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22729394 Free PMC article. Clinical Trial.
The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.Breast Cancer Res Treat. 2010 Jun;121(3):639-49. doi: 10.1007/s10549-009-0595-7. Epub 2009 Oct 30. Breast Cancer Res Treat. 2010. PMID: 19876733 Free PMC article. Clinical Trial.
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.J Natl Cancer Inst. 2011 Jan 19;103(2):105-16. doi: 10.1093/jnci/djq494. Epub 2010 Dec 17. J Natl Cancer Inst. 2011. PMID: 21169536 Free PMC article.
Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.Ann Oncol. 2011 Jan;22 Suppl 1:i11-7. doi: 10.1093/annonc/mdq660. Ann Oncol. 2011. PMID: 21285145 Review.
[Hereditary breast and ovarian cancer: primary and secondary prevention for BRCA1 and BRCA2 mutation carriers].Med Clin (Barc). 2007 Mar 31;128(12):468-76. doi: 10.1157/13100569. Med Clin (Barc). 2007. PMID: 17408542 Review. Spanish.
Cited by 10 articles
Identification of novel BRCA1 large genomic rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data.PeerJ. 2019 Nov 15;7:e7972. doi: 10.7717/peerj.7972. eCollection 2019. PeerJ. 2019. PMID: 31741787 Free PMC article.
Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer.PeerJ. 2019 Apr 22;7:e6661. doi: 10.7717/peerj.6661. eCollection 2019. PeerJ. 2019. PMID: 31065452 Free PMC article.
Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data.JCO Precis Oncol. 2018;2018:10.1200/PO.17.00148. doi: 10.1200/PO.17.00148. Epub 2018 Jan 19. JCO Precis Oncol. 2018. PMID: 30246169 Free PMC article.
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res. 2018 Oct;4(4):250-261. doi: 10.1002/cjp2.109. Epub 2018 Sep 21. J Pathol Clin Res. 2018. PMID: 30062862 Free PMC article.
Association of low penetrance vitamin D receptor Tru9I (rs757343) gene polymorphism with risk of premenopausal breast cancer.J Int Med Res. 2018 May;46(5):1801-1814. doi: 10.1177/0300060518761304. Epub 2018 Mar 12. J Int Med Res. 2018. PMID: 29529900 Free PMC article.
- U10 CA180868/CA/NCI NIH HHS/United States
- UL1 TR000430/TR/NCATS NIH HHS/United States
- A15007/Cancer Research UK/United Kingdom
- CA116201/CA/NCI NIH HHS/United States
- UG1 CA189867/CA/NCI NIH HHS/United States
- A8385/Cancer Research UK/United Kingdom
- R01 CA140323/CA/NCI NIH HHS/United States
- R01CA140323/CA/NCI NIH HHS/United States
- CA128978/CA/NCI NIH HHS/United States
- 1R01 CA149429-01/CA/NCI NIH HHS/United States
- P30 CA016672/CA/NCI NIH HHS/United States
- C1287/A16563/Cancer Research UK/United Kingdom
- C1287/A17523/Cancer Research UK/United Kingdom
- R01-CA102776/CA/NCI NIH HHS/United States
- P50 CA159981/CA/NCI NIH HHS/United States
- RC4 CA153828/CA/NCI NIH HHS/United States
- U10 CA101165/CA/NCI NIH HHS/United States
- C5047/A10692/Cancer Research UK/United Kingdom
- UM1 CA164920/CA/NCI NIH HHS/United States
- 11174/Cancer Research UK/United Kingdom
- P30 CA168524/CA/NCI NIH HHS/United States
- A10118/Cancer Research UK/United Kingdom
- A12014/Cancer Research UK/United Kingdom
- A10692/Cancer Research UK/United Kingdom
- RC4CA153828/CA/NCI NIH HHS/United States
- CA 27469/CA/NCI NIH HHS/United States
- U10 CA027469/CA/NCI NIH HHS/United States
- 1U19 CA148065/CA/NCI NIH HHS/United States
- A11174/Cancer Research UK/United Kingdom
- R25 CA174664/CA/NCI NIH HHS/United States
- C5047/A8384/Cancer Research UK/United Kingdom
- C12292/A11174/Cancer Research UK/United Kingdom
- R01 CA128978/CA/NCI NIH HHS/United States
- R01 CA083855/CA/NCI NIH HHS/United States
- Canadian Institutes of Health Research/Canada
- U19 CA148537/CA/NCI NIH HHS/United States
- P50 CA116201/CA/NCI NIH HHS/United States
- U01 CA113916/CA/NCI NIH HHS/United States
- U10 CA037517/CA/NCI NIH HHS/United States
- C1287/A 10710/Cancer Research UK/United Kingdom
- P30 CA015083/CA/NCI NIH HHS/United States
- R01-CA083855/CA/NCI NIH HHS/United States
- N02CP65504/CP/NCI NIH HHS/United States
- 5U01CA113916/CA/NCI NIH HHS/United States
- R01 CA102776/CA/NCI NIH HHS/United States
- C5047/A8385/Cancer Research UK/United Kingdom
- A17523/Cancer Research UK/United Kingdom
- M01 RR000043/RR/NCRR NIH HHS/United States
- U24 CA196067/CA/NCI NIH HHS/United States
- 1U19 CA148112/CA/NCI NIH HHS/United States
- 1U19CA148537/CA/NCI NIH HHS/United States
- C1281/A12014/Cancer Research UK/United Kingdom
- U19 CA148112/CA/NCI NIH HHS/United States
- R01 CA149429/CA/NCI NIH HHS/United States
- U19 CA148065/CA/NCI NIH HHS/United States
- 10119/Cancer Research UK/United Kingdom
- C1287/A10118/Cancer Research UK/United Kingdom
- U10 CA180867/CA/NCI NIH HHS/United States
- A16563/Cancer Research UK/United Kingdom
- 10118/Cancer Research UK/United Kingdom
- A10710/Cancer Research UK/United Kingdom
- U10 CA180822/CA/NCI NIH HHS/United States
- R01 CA126841/CA/NCI NIH HHS/United States
- C5047/A15007/Cancer Research UK/United Kingdom
- 10124/Cancer Research UK/United Kingdom
- N02CP11019/CP/NCI NIH HHS/United States